Latest take. After several emails and calls, I've gotten zero response on either. Since April's announcement on exploring options, latent P2 trial results expected first quarter, and continual depreciating market cap despite 54 million in cash and tangibles, we're either near a major reversal or the end of the end. With the Gene therapy sector gaining interests and consolidation, LOGC of latest in consolidation, we will either a see a conclusion or capitulation.
Last post here..